Analysts at RBC Capital Mkts, assumed coverage of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) with Outperform recommendation, according to their opinion released on July 16.
Short sellers are getting bullish about Xeris Pharmaceuticals, Inc. (NASDAQ:XERS). Looking at the sentiment indicator for the XERS stock we see that the short-interest ratio is at 13.35939 while the average analyst recommendations at 0 suggests selling these shares. Between January 15 and January 31, the total number of shorted shares amounted to 709.48 thousand shares. That was 16.21% less than the total of 846.74 thousand shares in the space of prior two weeks, which means more traders or funds betting that the stock will go up. Average daily volume for Xeris Pharmaceuticals, Inc. at the January 31st settlement jumped to 53,107, as compared to 34,073 at the January 15th report. That brought days to cover to a 46.24% decrease from the 24.85088 days to cover recorded at the prior short interest data release.
By watching the trading activity of corporate insiders, it will become easier to get a sense of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS)’s prospects. The earliest insider trade took place on 02/11/2019. Flynn James E parted with a total of 7.24 thousand shares of company at average share price of $15.09. The total for the sales was set at $109.27 thousand. After this transaction, the account balance stood at 2.36 million shares. The stock lost -30.15 percent since that insider sale. On 02/07/2019, Flynn James E, , sold 14.81 thousand shares at a price per share of $15.02. This removed 222.4 thousand shares from the insider’s fortune and the stock saw a -29.83 percent retreat in value since the news became public. This transaction left 2.36 million shares in the account. On 01/29/2019, Flynn James E performed a sale transaction worth $106.41 thousand. This sale at $15.12 each has eliminated 7.04 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -30.29 percent decrease since the transaction was reported. The insider now is left with 2.38 million shares remaining in the account. Flynn James E, who performs the job, sold 114.44 thousand shares for $1.77 million. The disposal occurred on 01/25/2019 was priced at $15.43 per share. The share price plunged -31.69 percent since the reporting date. Flynn James E now left with a stake of 2.38 million XERS stock worth $21.96 million after the insider selling.
Xeris Pharmaceuticals, Inc. (XERS) is expected to jump by 182.3 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $29 price as 12-month high target. This represents a whopping 214.88 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $25.5, which represents a return potential of 176.87 percent when compared to the closing price of the stock of $9.21 on Thursday, February 14. The lowest price target for the stock is $24 — slightly more than 160.59 percent from XERS’s current share price.
The shares are currently floating around the first support level of $9.02. Below this, the next support is placed in the zone of $8.82. Till the time, the XERS stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 15.5 on daily chart, which may remain a cause for comfort. If the price breaks below $8.82 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $9.6 mark may result into a pull-back move towards $9.98 level.
XERS shares dropped -1.33 points or -12.62 percent on Thursday to $9.21 with a light trade volume of 2.778 million shares. After opening the session at $9.5, the shares went as high as $9.79 and as low as $9.21, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $190 million and now has 20.67 million shares outstanding. Xeris Pharmaceuticals, Inc. (XERS) stock has lost -46.3 percent of market value in 21 trading days.
XERS stock has a trailing 3-year beta of 0, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$2.41 a share in the trailing twelve months. The stock’s value has fallen -45.82 percent year to date (YTD) against a decline of 0 percent in 12 month’s time. The company’s shares still trade -67.09 percent away from its 1-year high of $27.98 and -11.61 percent down from 52-week low of $10.42. The average consensus rating on the company is 0, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of Xeris Pharmaceuticals, Inc. (XERS) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry XERS operates in has an average P/E of 69.44. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 90.65 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 98 percent is the gross profit margin for Xeris Pharmaceuticals, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.